Clinical trial
The Preliminary Efficacy and Safety of AK104 Plus Concurrent Chemoradiation Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
NCT05594914 is registered in ClinicalTrials.gov with The First Affiliated Hospital of University of South China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Preliminary Efficacy and Safety of AK104 Plus Concurrent Chemoradiation Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Lead sponsor
- The First Affiliated Hospital of University of South China
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- October 31, 2022
- Completion date
- December 31, 2025
- Enrollment
- 47 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.